IP Library Granted Patent US 7,737,252
Granted Patent B2
US 7,737,252 · App. 10/395,500 · Granted Jun 15, 2010

Peptide-based compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,737,252
App. No.
10/395,500
Granted
Jun 15, 2010
Kind
B2
Abstract

This invention relates to new peptide-based compounds and their use in therapeutically effective treatments as well as for diagnostic imaging techniques. More specifically the invention relates to the use of such peptide-based compounds used as targeting vectors that bind to receptors associated with angiogenesis, in particular the αvβ3 integrin receptor. Such contrast agents may thus be used for diagnosis of for example malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma. Moreover such compounds may also be used in therapeutic treatment of these diseases.

Claims (26)

1. A compound of general formula (I)

wherein

r=0 or 1

p=0 or 1

and r+p=1

when r=0 the R 1 is —(CH 2 ) n —CO— or —(CH 2 ) n —C 6 H 4 —CO— where n=1, 2, 3, 4 or 5,

when r=1 then R 1 is one or more bridge-forming amino acids,

X i =an amino acid functionalized with a chelate capable of binding a reporter suitable for in vivo imaging,

X 2 and X 4 are independently cysteine,

X 3 is N-methylarginine,

X 5 is a hydrophobic amino acid,

X 6 is cysteine,

X 7 is a bond or linker

optionally allowing for labeling with chelates as defined by X 8 , and optionally comprising one or more ethylene glycol units or any other spacer component, and

X 8 is a chelate capable of binding a metal radionuclide or any other reporter suitable for in vivo imaging, or is NH 2 or is absent,

q is 0, 1, 2, 3, 4, 5, 6, 7, 8, and

one of the bridges, between R 1 and X 2 or between X 4 and X 6 , comprises a disulphide bond.

2. A compound as claimed in claim 1 wherein R 1 is cysteine.

3. A compound as claimed in claim 1 wherein X 6 is cysteine.

4. A compound as claimed in claim 1 wherein X 5 is tyrosine, iodotyrosine, diiodotyrosine or naphthylalanine.

5. A pharmaceutical composition comprising an effective amount of a compound of general formula (I) of claim 1 or an acid addition salt thereof to enhance image contrast for in vivo imaging or for therapeutic treatment, together with one or more pharmaceutically acceptable adjuvants, excipients or diluents.

6. A method of generating enhanced images of a human or non-human animal body which comprises administering to said body a pharmaceutical composition as claimed in claim 5 and generating an image of at least a part of said body.

7. A method of monitoring the effect of treatment of a human or non-human animal subject with a drug to combat a condition associated with angiogenesis which comprises administering to said subject a compound of formula I, of claim 1 , and detecting the uptake of said compound, said administration and detection optionally but preferably being effected repeatedly, e.g. before, during and after treatment with said drug.

8. The method of claim 7 , wherein said administration and detection are effected repeatedly.

9. The method of claim 8 , wherein said administration and detection are effected before, during and after treatment with said drug.

10. The method of claim 7 , wherein the compound of formula I is prepared by the step comprising metallating chelant groups to the compound of formula I with a metal ion detectable in a diagnostic imaging procedure.

Assignments (2)
CHANGE OF NAME Recorded Aug 2, 2006
From: AMERSHAM HEALTH AS; NYCOMED IMAGING AS
To: GE HEALTHCARE AS
Reel/Frame 018039/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2003
From: CUTHBERTSON, ALAN
To: AMERSHAM HEALTH AS
Reel/Frame 013979/0696 →